DHR at a glance
Danaher Corporation (DHR, SEC CIK 313616) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 21, 2026, an 8-K current report on October 21, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Danaher Corporation (DHR) reported revenue of $24.6 billion (up 2.9% from FY2024) and net income of $3.6 billion. Diluted EPS was $5.05.
- As of September 30, 2026, 62 institutional investment managers tracked by SignalX reported holding Danaher Corporation (DHR) shares worth $49.1 billion in 13F-HR filings.
- In the last 90 days, DHR insiders reported 0 open-market purchases ($0) and 6 open-market sales ($13.4M) on Form 4, a net sale of $13.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $24.6B
- +2.9% vs prior year
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$13.4M
- 13F holders
- 62 funds
- $49.1B · −5 vs prior quarter
- Latest 8-K
- Oct 21, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- IEEPA tariff authority struck down by U.S. Supreme Court Feb 2026; administration pursuing new tariffs under alternative authority: full impact still uncertain
- ~59% of 2025 sales from outside U.S.; China alone ~11% of sales, with government-mandated volume-based procurement programs actively suppressing prices
- Sole/limited-source suppliers for key components; supply interruptions cannot be quickly remedied due to regulatory qualification requirements
- $18.4B outstanding debt as of Dec 31, 2025; additional debt expected to finance pending Masimo Corporation acquisition
- FDA staffing reductions risk delays to 510(k) clearances and inspection schedules across Danaher's regulated medical device product lines
Business Overview
- Global science/technology platform across Biotechnology, Life Sciences, and Diagnostics segments; high recurring-revenue model via consumables and direct sales in ~50 countries
- ~60,000 employees (associates) as of Dec 31, 2025; ~22,000 in North America, ~20,000 Western Europe, ~15,000 high-growth markets
- US geographic concentration notable: North America represents 41% of sales in the United States alone; high-growth markets (Eastern Europe, Middle East, Africa, Latin America, Asia ex-Japan/AU/NZ) flagged as key future growth driver
- EU MDR/IVDR compliance deadlines extended to May 2026–Dec 2028 (MDR) and May 2026–May 2028 (IVDR), creating ongoing regulatory adaptation burden across Diagnostics and Life Sciences portfolios
- Life Sciences segment anchors on 2023 Abcam acquisition (protein consumables/antibodies), the most recent portfolio addition, reinforcing proteomics and drug-discovery consumables as strategic build-out priority
Management Discussion & Analysis
- Revenue $24.6B, up 3.0% YoY; core sales +2.0% driven by Biotechnology (+6.5% core) and Diagnostics (+1.5% core), offset by Life Sciences (-1.5% core)
- Operating margin 19.1% vs 20.4%; gross margin 59.1% vs 59.5%; SG&A 33.5% vs 32.5% of sales, pressured by $533M impairment charges
- Best segment: Biotechnology, sales $7.3B (+8.0%), operating margin 25.6% vs 24.9%; worst: Life Sciences, flat sales $7.3B, operating margin collapsed to 7.1% vs 12.0%
- Operating cash flow $6.4B; capex $1.2B; share buybacks $3.1B; dividends $878M; net debt rose to ~$18.4B total debt vs $16.0B in 2024
- 2026 outlook: Bioprocessing growth trend similar to 2025; Life Sciences modest improvement but below historical levels; Diagnostics higher growth as China headwinds ease; tariff costs <$300M in 2025 with ongoing uncertainty from trade policy shifts
AI summary of the DHR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 25, 2026
Risk Factors
- New military-conflict risk, triggered by 2026 conflict across multiple Middle Eastern countries
- Operational disruption: Middle East conflict affecting energy supplies and supply chains
- Financial volatility: increased energy and supply costs from Middle East hostilities
- Market risk: conflict-driven capital-market volatility affecting financial statements
Management Discussion & Analysis
- Revenue $6.554B, up 8.5% YoY from $6.053B, with core sales up 3.0%
- Operating margin 19.0% vs 19.1% YoY; gross margin 58.5% vs 58.2%
- Best segment Diagnostics: sales $2.882B, up 17.0%; worst margin trend, 21.3% vs 27.0%
- Operating cash flow $4.742B, up $443M; cash $5.7B, Masimo acquisition cash payment $9.881B
- Outlook: full-year effective tax rate approximately 17.0%; respiratory demand and tariff impacts remain uncertain
AI summary of the DHR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Danaher announced financial results for the quarter ended September 25, 2026
- Earnings details and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $6.6B, up 8.5%, with core growth excluding respiratory testing accelerating to 5.5%
- Net earnings $1.2B, or $1.71 diluted EPS, up 34.5%; adjusted EPS $2.11, up 11.5%
Item 8.01: Other Events
- Steven and Mitchell Rales waived Founder RSUs covering 500,000 shares each, reducing potential equity dilution
- Waivers received no consideration, eliminating the associated share-based compensation benefit
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded to 13 members with immediate appointments of former CFO Daniel Comas and biotech executive Robert Hershberg
- Comas brings Danaher finance, treasury, risk management and corporate development experience, strengthening board-level financial oversight
Item EX-99.1: Item EX-99.1
- Julie Sawyer Montgomery becomes CEO and board member October 1, 2026, marking a planned leadership succession
- Rainer Blair retires October 1 after six years as CEO, remaining senior advisor through March 31, 2027
Item 7.01: Regulation FD Disclosure
- Press release announces the leadership transition described in Item 5.02
- Exhibit 99.1 contains the company’s detailed transition announcement
Item 8.01: Other Events
- Special awards for each Rales: options on 1,000,000 shares plus RSUs on 500,000 shares
- Vesting: 50% on the fourth anniversary and 50% on the fifth anniversary, subject to continued employment
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Julie Sawyer Montgomery becomes CEO and director October 1, 2026, succeeding Rainer Blair after extensive Danaher operating experience
- CEO compensation: $1.5M salary, 200% target cash incentive, $13.2M 2027 long-term award
AI summaries of DHR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DHR
Don't miss the next DHR filing
- Alerts as it files. A push when DHR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DHR, by share count.
- Ask anything. An AI agent that reads every DHR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sawyer Montgomery Julie A | F | Nov 15, 2026 | 261 | $233.02 |
| HERSHBERG ROBERT | A | Nov 15, 2026 | 282 | - |
| Moler Heathre T | A | Nov 15, 2026 | 67,575 | - |
| COMAS DANIEL L | A | Nov 15, 2026 | 282 | - |
| Moler Heathre T | F | Nov 15, 2026 | 37 | $233.02 |
| Leiken Jonathan | F | Nov 15, 2026 | 1,122 | $233.02 |
| Muppaneni Shashanka | F | Nov 15, 2026 | 122 | $233.02 |
| COMAS DANIEL L | A | Nov 15, 2026 | 663 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $23.9B | $24.6B |
| Gross Profit | - | $14.2B | $14.5B |
| Operating Income | - | $4.9B | $4.7B |
| Net Income | - | $3.9B | $3.6B |
| Gross Margin | - | 59.5% | 59.1% |
| Op. Margin | - | 20.4% | 19.1% |
| Net Margin | - | 16.3% | 14.7% |
| Balance Sheet | |||
| Total Assets | $84.5B | $77.5B | $83.5B |
| Equity | - | $49.5B | $52.5B |
| ROE | - | 7.9% | 6.9% |
| Per Share | |||
| EPS | - | $5.29 | $5.05 |
| Cash Flow | |||
| Operating CF | - | $6.7B | $6.4B |
| CapEx | $1.4B | $1.4B | $1.2B |
Source: XBRL data in Danaher Corporation (DHR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate DHR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 62 | $49.10B |
| Q2 2026 | 67 | $49.05B |
| Q1 2026 | 65 | $48.74B |
| Q4 2025 | 66 | $59.57B |
| Q3 2025 | 67 | $54.89B |
| Q2 2025 | 66 | $49.59B |
| Q1 2025 | 63 | $38.03B |
| Q4 2024 | 63 | $36.39B |
- JPMorgan Chase & Co+1.72M (+14%)
- BNY Mellon+1.29M (+35%)
- Tiger Global Management+812.8K (+178%)
- Goldman Sachs Group+414.2K (+8%)
- Bridgewater Associates LP+370.6K (+1443%)
- T. Rowe Price Group−4.07M (-36%)
- Principal Financial Group−2.02M (-76%)
- AQR Capital Management−1.26M (-48%)
- BlackRock−1.11M (-2%)
- Millennium Management−894.3K (-42%)
- Viking Global Investors+1.04M
- Finward Bancorp+1.0K
- FMR LLC (Fidelity)−29.54M
- Renaissance Technologies LLC−760.6K
- Third Point LLC−540.0K
- Loews Corporation−75.0K
- Equitable Holdings Inc−15.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 519 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DHR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Oct 29, 2026 | - | - | - |
| 4 | Oct 29, 2026 | - | - | - |
| 8-K | Oct 21, 2026 | - | Analysis | - |
| 10-Q | Oct 21, 2026 | Sep 25, 2026 | Analysis | |
| 4 | Oct 14, 2026 | - | - | - |
| 4 | Oct 14, 2026 | - | - | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Aug 24, 2026 | - | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- ACHC · Acadia Healthcare Company IncServices-Specialty Outpatient Facilities, NEC
DHR SEC filings: frequently asked questions
Are DHR insiders buying or selling?
In the last 90 days, Danaher Corporation (DHR) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $13.4 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold DHR stock?
As of September 30, 2026, the largest Danaher Corporation (DHR) holders among the 13F filers tracked by SignalX were BlackRock ($12.0 billion), Vanguard Capital Management LLC ($9.1 billion), State Street Corp ($6.3 billion), Vanguard Portfolio Management LLC ($3.2 billion), JPMorgan Chase & Co ($3.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was DHR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Danaher Corporation (DHR) reported revenue of $24.6 billion (up 2.9% from FY2024) and net income of $3.6 billion. Diluted EPS was $5.05. The figures come from the XBRL data in the 10-K.
What are the main risks in DHR's latest 10-K?
In the 10-K filed February 24, 2026, Danaher Corporation (DHR) flagged: IEEPA tariff authority struck down by U.S. Supreme Court Feb 2026; administration pursuing new tariffs under alternative authority: full impact still uncertain. ~59% of 2025 sales from outside U.S.; China alone ~11% of sales, with government-mandated volume-based procurement programs actively suppressing prices. (AI summary of the Risk Factors section.)
What did DHR report in its latest 8-K?
Danaher Corporation (DHR) filed an 8-K on October 21, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Danaher announced financial results for the quarter ended September 25, 2026.
What are the latest DHR SEC filings?
Danaher Corporation (DHR) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 21, 2026, an 8-K current report on October 21, 2026 and a Form 4 insider filing on November 17, 2026.
What is DHR's SEC CIK number?
Danaher Corporation (DHR)'s SEC Central Index Key (CIK) is 313616. EDGAR lists every DHR filing under that number.
Ask anything about DHR
The research agent reads DHR's filings, financials, insider trades and 13F holders, then answers with sources.